Hospital
Loma Linda University Medical Center-Murrieta
Loma Linda University Medical Center-Murrieta was paid $70.86M by Medicaid between Jan 2018 and Nov 2024, across 357 billing codes. Its largest line is 99283, emergency room visit (moderate) — 47% of everything it billed.
33Billing provider infoLOMA LINDA UNIVERSITY MEDICAL CENTER-MURRIETA
MURRIETA, CA 92563
MURRIETA, CA 92563
33aNPI1588908388assigned 11/16/2012
33bProvider typeGeneral Acute Care Hospital
28Total paid$70.86M
24GClaims1,008,067
24DCodes billed357
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other General Acute Care Hospital providers in California
Rank by total paid#38 of 410
Median peer was paid$6.90M
This provider vs. median10×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 114,020 | $5.06M | |
| 2019 | 117,150 | $6.40M | |
| 2020 | 105,079 | $7.51M | |
| 2021 | 122,972 | $8.59M | |
| 2022 | 157,240 | $11.56M | |
| 2023 | 191,469 | $15.77M | |
| 2024incomplete | 200,137 | $15.97M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 47% | 42,676 | 38,930 | $32.97M |
| 0450 | Emergency room services | 35% | 48,703 | 43,432 | $24.47M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 4.8% | 13,280 | 12,355 | $3.43M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 10,369 | 10,163 | $666K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | <1% | 3,282 | 3,234 | $585K |
| 93458 | <1% | 536 | 502 | $494K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 19,840 | 18,429 | $478K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | <1% | 8,632 | 8,549 | $457K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 11,324 | 11,046 | $420K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 9,337 | 9,083 | $388K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 9,517 | 9,267 | $305K |
| 71045 | Radiologic examination, chest; single view | <1% | 27,824 | 25,973 | $277K |
345 more codes
| L8699 | Prosthetic implant, not otherwise specified | <1% | 112 | $259K |
| 80053 | Comprehensive metabolic panel | <1% | 55,014 | $225K |
| 0360 | <1% | 1,555 | $201K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 8,737 | $197K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 6,894 | $190K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 16,745 | $181K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 4,955 | $167K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 1,008 | $154K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 1,094 | $130K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 5,306 | $117K |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 744 | $113K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 21,148 | $104K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 2,305 | $102K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 882 | $102K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 9,307 | $99K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 4,002 | $96K |
| 99232 | Hospital visit by a doctor, follow-up day | <1% | 1,408 | $96K |
| 99221 | <1% | 619 | $94K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 952 | $86K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 1,619 | $86K |
| 99223 | Prolong inpt eval add15 m | <1% | 653 | $80K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 11,321 | $80K |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 721 | $72K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 861 | $67K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 12,311 | $65K |
| 0510 | <1% | 1,859 | $65K | |
| 99233 | Hospital visit by a doctor, follow-up day (complex) | <1% | 701 | $63K |
| J3490 | Unclassified drugs | <1% | 33,170 | $62K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 50,585 | $62K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,452 | $61K |
| 82962 | <1% | 12,171 | $57K | |
| Z7502 | <1% | 1,485 | $56K | |
| 99070 | <1% | 44,209 | $56K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 6,011 | $54K |
| 76830 | Ultrasound, transvaginal | <1% | 2,180 | $52K |
| 93971 | <1% | 2,704 | $51K | |
| 76801 | <1% | 2,169 | $50K | |
| 0710 | <1% | 1,067 | $50K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 1,071 | $49K |
| 93970 | <1% | 1,314 | $48K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 3,145 | $47K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 1,744 | $44K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 247 | $41K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 1,180 | $41K |
| 99222 | Initial hospital care, per day, moderate complexity | <1% | 381 | $40K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 9,761 | $40K |
| 76770 | <1% | 1,341 | $37K | |
| 85730 | <1% | 25,880 | $37K | |
| 59409 | Vaginal delivery only (with or without episiotomy and/or forceps) | <1% | 45 | $37K |
| 92004 | Ophthalmological services: medical examination and evaluation, comprehensive, new patient | <1% | 237 | $36K |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 7,613 | $33K |
| 99239 | Hospital discharge day management, more than 30 minutes | <1% | 289 | $31K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 3,930 | $30K |
| 59025 | Fetal non-stress test | <1% | 769 | $29K |
| 81001 | <1% | 38,563 | $29K | |
| 99238 | Hospital discharge day management, 30 minutes or less | <1% | 716 | $28K |
| 85610 | <1% | 26,257 | $26K | |
| 84484 | <1% | 24,937 | $26K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 442 | $26K |
| 73630 | <1% | 2,834 | $25K | |
| 85027 | <1% | 8,176 | $24K | |
| 84703 | <1% | 19,118 | $24K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 6,841 | $23K |
| 99231 | Subsequent hospital care, per day, straightforward or low complexity | <1% | 390 | $23K |
| 99205 | Prolong outpt/office vis | <1% | 115 | $23K |
| 83690 | <1% | 17,458 | $22K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 231 | $22K |
| 97750 | <1% | 559 | $21K | |
| 87088 | <1% | 11,742 | $21K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 3,641 | $21K |
| 70496 | <1% | 306 | $20K | |
| 49083 | <1% | 306 | $20K | |
| 74018 | <1% | 3,565 | $20K | |
| 72131 | <1% | 792 | $20K | |
| 83880 | <1% | 5,920 | $20K | |
| 31579 | <1% | 139 | $20K | |
| 70486 | <1% | 509 | $18K | |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 81 | $18K |
| 70498 | <1% | 286 | $18K | |
| 92060 | <1% | 270 | $17K | |
| 74183 | <1% | 188 | $17K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 2,938 | $14K |
| 92579 | <1% | 314 | $14K | |
| J2704 | Injection, propofol, 10 mg | <1% | 2,499 | $14K |
| 83605 | <1% | 7,723 | $14K | |
| 87040 | <1% | 5,957 | $13K | |
| 92567 | <1% | 764 | $13K | |
| 93303 | Transthoracic echocardiography for congenital cardiac anomalies, follow-up or limited study | <1% | 153 | $13K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 3,618 | $12K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 1,353 | $12K |
| 99218 | <1% | 72 | $12K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 905 | $12K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 3,359 | $12K |
| 92582 | <1% | 127 | $12K | |
| 66984 | Extracapsular cataract removal with insertion of intraocular lens prosthesis | <1% | 27 | $11K |
| 92587 | <1% | 521 | $11K | |
| 73030 | <1% | 1,746 | $11K | |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 54 | $11K |
| 86900 | <1% | 5,545 | $11K | |
| 73610 | <1% | 1,827 | $11K | |
| 82550 | <1% | 12,613 | $11K | |
| Z9725 | <1% | 246 | $10K | |
| 86850 | <1% | 3,523 | $10K | |
| 72197 | <1% | 108 | $10K | |
| 92014 | Ophthalmological services: medical examination and evaluation, comprehensive, established patient | <1% | 81 | $10K |
| 73130 | <1% | 1,821 | $10K | |
| 0720 | <1% | 288 | $10K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 4,071 | $10K |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 6,667 | $9K |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 2,547 | $9K |
| 72100 | <1% | 1,759 | $9K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 1,061 | $9K |
| 83735 | <1% | 7,298 | $9K | |
| 99460 | <1% | 93 | $9K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 124 | $9K |
| 86328 | <1% | 242 | $9K | |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 66 | $8K |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 4,795 | $8K |
| 95720 | <1% | 48 | $8K | |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 1,133 | $8K |
| 71250 | <1% | 218 | $8K | |
| 92015 | Determination of refractive state | <1% | 631 | $8K |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 1,221 | $7K |
| 87070 | <1% | 2,917 | $7K | |
| 86901 | <1% | 5,115 | $7K | |
| 76536 | <1% | 255 | $7K | |
| 69210 | <1% | 243 | $7K | |
| 84702 | <1% | 3,326 | $7K | |
| 90960 | End-stage renal disease related services monthly, for patients 20 years and older, with 4 or more face-to-face visits | <1% | 37 | $7K |
| 93000 | <1% | 558 | $6K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 15,308 | $6K |
| 0250 | <1% | 3,238 | $6K | |
| 87077 | <1% | 7,292 | $6K | |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | <1% | 166 | $6K |
| 0750 | <1% | 58 | $6K | |
| 82553 | <1% | 6,508 | $6K | |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 54 | $6K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 174 | $5K |
| 92557 | <1% | 138 | $5K | |
| 96367 | <1% | 385 | $5K | |
| 88307 | <1% | 54 | $5K | |
| 51798 | <1% | 150 | $5K | |
| 96376 | <1% | 1,568 | $5K | |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 95 | $5K |
| 74178 | <1% | 54 | $5K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 81 | $5K |
| 73562 | <1% | 910 | $5K | |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 156 | $5K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 149 | $4K |
| G2211 | Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) | <1% | 366 | $4K |
| 72040 | <1% | 812 | $4K | |
| 87430 | <1% | 2,855 | $4K | |
| 52000 | <1% | 59 | $4K | |
| 0370 | <1% | 13 | $4K | |
| 00920 | <1% | 31 | $4K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 12,286 | $4K |
| J0136 | Injection, acetaminophen (b braun), not therapeutically equivalent to j0131, 10 mg | <1% | 485 | $4K |
| 85379 | <1% | 2,227 | $4K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 712 | $4K |
| 93248 | <1% | 176 | $3K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 708 | $3K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 8,058 | $3K |
| 99217 | <1% | 109 | $3K | |
| 76825 | <1% | 40 | $3K | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 356 | $3K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 4,146 | $3K |
| 70491 | <1% | 52 | $3K | |
| 73564 | <1% | 311 | $3K | |
| 76376 | <1% | 421 | $3K | |
| 75574 | <1% | 35 | $3K | |
| 86140 | <1% | 2,694 | $3K | |
| 74174 | <1% | 36 | $3K | |
| 92556 | <1% | 59 | $3K | |
| 93320 | <1% | 154 | $3K | |
| 31575 | <1% | 29 | $3K | |
| 97799 | <1% | 180 | $3K | |
| 97165 | <1% | 69 | $2K | |
| 00170 | Anesthesia for intraoral procedures, including biopsy | <1% | 13 | $2K |
| 93976 | <1% | 77 | $2K | |
| 76937 | <1% | 277 | $2K | |
| 80143 | <1% | 907 | $2K | |
| 73590 | <1% | 620 | $2K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 5,188 | $2K |
| 76776 | <1% | 110 | $2K | |
| G0121 | Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | <1% | 12 | $2K |
| 92012 | Ophthalmological services: medical examination and evaluation, intermediate, established patient | <1% | 30 | $2K |
| 93325 | <1% | 457 | $2K | |
| 93228 | <1% | 87 | $2K | |
| 88341 | <1% | 16 | $2K | |
| 99224 | <1% | 28 | $2K | |
| 99152 | <1% | 227 | $2K | |
| 93351 | <1% | 26 | $2K | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 263 | $2K |
| 73110 | <1% | 466 | $2K | |
| 97602 | <1% | 63 | $2K | |
| 84100 | <1% | 1,891 | $2K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 38 | $2K |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 2,856 | $2K |
| 84439 | <1% | 1,033 | $2K | |
| 52310 | <1% | 13 | $2K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 2,281 | $2K |
| 0272 | <1% | 1,011 | $2K | |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 405 | $2K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 2,728 | $2K |
| 85652 | <1% | 2,557 | $2K | |
| 85007 | <1% | 2,719 | $2K | |
| 97763 | <1% | 46 | $2K | |
| 88350 | <1% | 12 | $2K | |
| 87400 | <1% | 2,741 | $1K | |
| 73090 | <1% | 395 | $1K | |
| 73080 | <1% | 253 | $1K | |
| J0134 | Injection, acetaminophen (fresenius kabi), not therapeutically equivalent to j0131, 10 mg | <1% | 136 | $1K |
| 86923 | <1% | 110 | $1K | |
| 0270 | <1% | 1,056 | $1K | |
| 81003 | <1% | 563 | $1K | |
| 87147 | <1% | 1,902 | $1K | |
| P9047 | Infusion, albumin (human), 25%, 50 ml | <1% | 25 | $1K |
| 76642 | <1% | 41 | $1K | |
| 99308 | Subsequent nursing facility care, per day, straightforward | <1% | 56 | $1K |
| 76827 | <1% | 39 | $1K | |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | <1% | 13 | $1K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 30 | $1K |
| 81025 | <1% | 1,615 | $1K | |
| 88342 | <1% | 36 | $1K | |
| 87205 | <1% | 792 | $1K | |
| 51784 | <1% | 15 | $1K | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 18 | $1K |
| 93312 | <1% | 12 | $987.31 | |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 20 | $950.08 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 2,219 | $934.89 |
| 72070 | <1% | 262 | $924.54 | |
| 90715 | <1% | 432 | $882.20 | |
| 93975 | <1% | 18 | $867.88 | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 14 | $864.20 |
| 76942 | <1% | 13 | $792.00 | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 255 | $785.95 |
| 99153 | Mod sedat endo service >5yrs | <1% | 27 | $778.19 |
| 93283 | <1% | 20 | $761.72 | |
| 86308 | <1% | 987 | $752.63 | |
| 92134 | <1% | 25 | $702.86 | |
| 82330 | <1% | 146 | $694.38 | |
| G0500 | Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monitoring of the patient's level of consciousness and physiological status; initial 15 minutes of intra-service time; patient age 5 years or older (additional time may be reported with 99153, as appropriate) | <1% | 136 | $683.49 |
| 82803 | <1% | 128 | $681.21 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 2,350 | $676.56 |
| 88313 | <1% | 24 | $642.90 | |
| 86318 | <1% | 171 | $633.46 | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 74 | $623.75 |
| 92083 | <1% | 14 | $609.14 | |
| 93284 | <1% | 14 | $608.41 | |
| 73501 | <1% | 125 | $566.02 | |
| 12001 | <1% | 100 | $561.66 | |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 15 | $529.46 |
| 87186 | <1% | 412 | $522.36 | |
| 0100U | <1% | 224 | $520.84 | |
| 73560 | <1% | 167 | $514.17 | |
| 82570 | <1% | 117 | $497.57 | |
| 0259 | <1% | 2,572 | $493.00 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 506 | $478.61 |
| 29125 | <1% | 173 | $477.43 | |
| 76870 | <1% | 24 | $469.91 | |
| A9270 | Non-covered item or service | <1% | 4,565 | $469.87 |
| 95816 | <1% | 13 | $464.00 | |
| 92136 | <1% | 13 | $447.75 | |
| 84132 | <1% | 261 | $447.36 | |
| Z7610 | <1% | 47 | $420.62 | |
| 93244 | <1% | 26 | $405.27 | |
| 76882 | <1% | 13 | $405.16 | |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 56 | $402.88 |
| 88304 | <1% | 35 | $400.68 | |
| 82274 | <1% | 234 | $390.75 | |
| 87420 | <1% | 603 | $378.93 | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 383 | $336.52 |
| 74230 | <1% | 13 | $322.52 | |
| 84550 | <1% | 200 | $306.03 | |
| S0020 | Injection, bupivicaine hydrochloride, 30 ml | <1% | 67 | $297.25 |
| 73502 | <1% | 14 | $289.66 | |
| 88346 | <1% | 12 | $286.66 | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 26 | $275.70 |
| 83615 | <1% | 1,346 | $265.46 | |
| 93016 | <1% | 18 | $264.23 | |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | <1% | 25 | $258.62 |
| 73565 | <1% | 31 | $219.19 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 245 | $217.77 |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 55 | $209.36 |
| 72170 | <1% | 32 | $205.96 | |
| 93227 | <1% | 12 | $192.62 | |
| 85014 | <1% | 124 | $181.54 | |
| 82150 | <1% | 268 | $178.60 | |
| J1920 | Injection, labetalol hydrochloride, 5 mg | <1% | 24 | $176.27 |
| 93018 | <1% | 18 | $174.33 | |
| 84295 | <1% | 124 | $168.77 | |
| S0164 | Injection, pantoprazole sodium, 40 mg | <1% | 491 | $161.34 |
| A6453 | Self-adherent bandage, elastic, non-knitted/non-woven, width less than three inches, per yard | <1% | 116 | $145.48 |
| 73060 | <1% | 40 | $134.31 | |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | <1% | 63 | $128.49 |
| 71020 | <1% | 172 | $127.14 | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 13 | $126.61 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 240 | $114.58 |
| 51741 | <1% | 15 | $112.50 | |
| 85378 | <1% | 295 | $112.22 | |
| 81002 | <1% | 87 | $108.63 | |
| 0271 | <1% | 117 | $103.00 | |
| E0112 | Crutches underarm, wood, adjustable or fixed, pair, with pads, tips and handgrips | <1% | 124 | $101.66 |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 197 | $95.72 |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 210 | $89.09 |
| 71100 | <1% | 51 | $86.81 | |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 36 | $85.14 |
| 87184 | <1% | 107 | $83.96 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 265 | $77.31 |
| 73140 | <1% | 12 | $76.94 | |
| 84156 | <1% | 34 | $69.32 | |
| 82728 | <1% | 13 | $65.12 | |
| 84436 | <1% | 233 | $59.20 | |
| 0258 | <1% | 514 | $53.48 | |
| 29515 | <1% | 24 | $39.37 | |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 26 | $32.00 |
| 36410 | <1% | 160 | $27.24 | |
| 74022 | <1% | 41 | $26.81 | |
| 87280 | <1% | 130 | $24.85 | |
| S0077 | Injection, clindamycin phosphate, 300 mg | <1% | 12 | $21.88 |
| 87210 | <1% | 45 | $21.78 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 96 | $21.48 |
| J0456 | Injection, azithromycin, 500 mg | <1% | 37 | $16.88 |
| J1815 | Injection, insulin, per 5 units | <1% | 47 | $15.00 |
| J2470 | Injection, pantoprazole sodium, 40 mg | <1% | 92 | $13.82 |
| 82270 | <1% | 13 | $7.86 | |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 31 | $5.60 |
| Q0144 | Azithromycin dihydrate, oral, capsules/powder, 1 gram | <1% | 26 | $4.96 |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 131 | $4.20 |
| 99499 | 0% | 90 | $0.00 | |
| G8484 | Influenza immunization was not administered, reason not given | 0% | 16 | $0.00 |
| 73100 | 0% | 27 | $0.00 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 0% | 65 | $0.00 |
| 86999 | 0% | 51 | $0.00 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | 0% | 18 | $0.00 |
| G8427 | Eligible clinician attests to documenting in the medical record they obtained, updated, or reviewed the patient's current medications | 0% | 20 | $0.00 |
| 3078F | 0% | 26 | $0.00 | |
| 71010 | 0% | 119 | $0.00 | |
| 74019 | 0% | 59 | $0.00 | |
| G8510 | Screening for depression is documented as negative, a follow-up plan is not required | 0% | 812 | $0.00 |
| 73552 | 0% | 39 | $0.00 | |
| 85651 | 0% | 26 | $0.00 | |
| J7042 | 5% dextrose/normal saline (500 ml = 1 unit) | 0% | 13 | $0.00 |
| 3074F | 0% | 15 | $0.00 | |
| 36430 | 0% | 14 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialHILLIARD, ANTHONY (CEO)
| Provider | Location | Paid |
|---|---|---|
| Loma Linda University Children's Hospital | Loma Linda, CA | $107.10M |
| Seventh-Day Adventists Loma Linda University Medical Center | Redlands, CA | $19.31M |
| Seventh-Day Adventists Loma Linda University Medical Center | Loma Linda, CA | $13.94M |
| Seventh-Day Adventists Loma Linda University Medical Center | Loma Linda, CA | $2.13M |
| Seventh-Day Adventists Loma Linda University Medical Center | Loma Linda, CA | $227K |
| Loma Linda University Children's Hospital | Loma Linda, CA | $194K |
| Seventh-Day Adventists Loma Linda University Medical Center | Loma Linda, CA | $4K |
| Seventh-Day Adventists Loma Linda University Medical Center | Loma Linda, CA | $3K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.